

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT:	Mansoor Safarazi	)
		) Group Art Unit:
SERIAL NO.:	10/609,133	) 1634
		)
FILED:	June 26, 2003	) Before the Examiner:
		) Sitton
FOR:	OPTINEURIN AND GLAUCOMA	)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT**  
**PURSUANT TO 35 U.S.C. §121**

Sir:

This is in response to the Notice of Noncompliant Amendment dated May 5, 2006. The Examiner has required that Applicants elect a specific variant for claims 3 and 10. The Examiner noted that should linking claims 1 and 8 directed to “any” variation become allowable, the restriction requirement between the variants listed in claims 3 and 10 will be withdrawn. Applicants elect in claims 3 and 10 a change from GAG to AAG at codon 50, corresponding to a change from glutamic acid to lysine at codon 50. Applicants hereby traverse the restriction. Because all of the mutations listed in claims 3 and 10 are mutations in the optineurin gene, it would not present an undue burden to search multiple mutations.

If there are any charges with respect to this Restriction Requirement, or otherwise, please charge them to Deposit Account No. 06-1130.

Respectfully submitted,

CANTOR COLBURN LLP

By: Karen A. LeCuyer  
Karen A. LeCuyer  
Registration No. 51,928  
Customer No. 23413

Date: May 22, 2006  
Telephone: (860) 286-2929